WAYNE, Pa., Dec. 17, 2015
/PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"),
a fully integrated specialty pharmaceutical company focused on
developing, manufacturing and commercializing innovative treatments
for pain and other conditions, announced that it has been selected
for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI)
effective Monday, December 21,
2015.
Companies in the NBI must meet eligibility requirements,
including minimum market capitalization, average daily trading
volume, and seasoning as a public company, among other criteria.
The index is evaluated semi-annually in May and November and serves
as the basis for the iShares NASDAQ Biotechnology Index Fund. The
Index is designed to track the performance of a set of securities
listed on the NASDAQ Stock Market that are classified as either
biotechnology or pharmaceutical according to the Industry
Classification Benchmark (ICB). For more information about the
NASDAQ Biotechnology Index, including eligibility criteria, visit
https://indexes.nasdaqomx.com/. Egalet is also included in the
Russell Global 3000, Russell 2000 and Russell Global indices.
About Egalet
Egalet, a fully integrated specialty
pharmaceutical company, is focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions. The Company has two approved products: OXAYDO™
(oxycodone HCI, USP) tablets for oral use only –CII and
SPRIX® (ketorolac tromethamine) Nasal Spray. In
addition, using Egalet's proprietary Guardian™ Technology, the
Company is developing a pipeline of clinical-stage, opioid-based
product candidates that are specifically designed to deter abuse by
physical and chemical manipulation. The lead programs, ARYMO™
ER, formerly known as Egalet-001, an abuse-deterrent,
extended-release, oral morphine formulation, and Egalet-002, an
abuse-deterrent, extended-release, oral oxycodone formulation, are
being developed for the management of pain severe enough to require
daily, around-the-clock opioid treatment and for which alternative
treatments are inadequate. Egalet's Guardian Technology can be
applied broadly across different classes of pharmaceutical products
and can be used to develop combination products that include
multiple active pharmaceutical ingredients with similar or
different release profiles. For full prescribing information on
SPRIX, including the Boxed Warning, please visit sprix.com.
For full prescribing information on OXAYDO, please visit
oxaydo.com. For additional information on Egalet, please visit
egalet.com.
Safe Harbor
Statements included in this press release
(including but not limited to upcoming milestones) that are not
historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on management's current
expectations, and are subject to known and unknown uncertainties
and risks. Actual results could differ materially from those
discussed due to a number of factors, including, but not limited
to: the success of Egalet's clinical trials, including the timely
recruitment of trial subjects and meeting the timelines therefor;
Egalet's ability to obtain regulatory approval of Egalet's product
candidates; Egalet's ability to maintain the intellectual property
position of Egalet's products and product candidates; Egalet's
ability to identify and reliance upon qualified third parties to
manufacture its products; Egalet's ability to service its debt
obligations; Egalet's ability to find and hire qualified sales
professionals; the receptivity in the marketplace and among
physicians to Egalet's products; the success of products which
compete with Egalet's that are or become available; general market
conditions; and other risk factors described in Egalet's filings
with the United States Securities and Exchange Commission. Egalet
assumes no obligation to update or revise any
forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be
required by law.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
Logo -
http://photos.prnewswire.com/prnh/20140219/NY67493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/egalet-added-to-nasdaq-biotechnology-index-300194092.html
SOURCE Egalet Corporation
